More funding, fewer winners?
One thing that is clear from our Q2 biotech report is that funding and opportunity don't always move in the same direction.
As we highlighted last week, funding increased significantly in Q2, but the number of funding rounds actually fell. At the same time, 89% of all funding sat within just five funding rounds.
That suggests there is still plenty of capital available, but investors are becoming increasingly selective about where they place it.
For biotech businesses looking to scale, that creates both opportunity and challenges.
Our Q2 biotech market report is available now, just reach out to the team info@nextphaserecruitment.com
One thing that is clear from our Q2 biotech report is that funding and opportunity don't always move in the same direction.
As we highlighted last week, funding increased significantly in Q2, but the number of funding rounds actually fell. At the same time, 89% of all funding sat within just five funding rounds.
That suggests there is still plenty of capital available, but investors are becoming increasingly selective about where they place it.
For biotech businesses looking to scale, that creates both opportunity and challenges.
Our Q2 biotech market report is available now, just reach out to the team info@nextphaserecruitment.com